Literature DB >> 15452233

Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates.

Andre J Marozsan1, Erika Fraundorf, Awet Abraha, Heather Baird, Dawn Moore, Ryan Troyer, Immaculate Nankja, Eric J Arts.   

Abstract

Most studies on human immunodeficiency virus type 1 (HIV-1) replication kinetics or fitness must rely on a particular assay to initially standardize inocula from virus stocks. The most accurate measure of infectious HIV-1 titers involves a limiting dilution-infection assay and a calculation of the dose required for 50% infectivity of susceptible cells in tissue culture (TCID(50)). Surrogate assays are now commonly used to measure the amount of p24 capsid, the endogenous reverse transcriptase (RT) activity, or the amount of viral genomic RNA in virus particles. However, a direct comparison of these surrogate assays and actual infectious HIV-1 titers from TCID(50) assays has not been performed with even the most conserved laboratory strains, let alone the highly divergent primary HIV-1 isolates of different subtypes. This study indicates that endogenous RT activity, not p24 content or viral RNA load, is the best surrogate measure of infectious HIV-1 titer in both cell-free supernatants and viruses purified on sucrose cushions. Sequence variation between HIV-1 subtypes did not appear to affect the function or activity of the RT enzyme in this endogenous assay but did affect the detection of p24 capsid by both enzyme immunoassays and Western blots. Clear groupings of non-syncytium-inducing (NSI), CCR5-tropic (R5), and SI/CXCR4-tropic (X4) HIV-1 isolates were observed when we compared the slopes derived from correlations of RT activity with infectious titers. Finally, the replication efficiency or fitness of both the NSI/R5 and SI/X4 HIV-1 isolates was not linked to the titers of the virus stocks.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452233      PMCID: PMC521859          DOI: 10.1128/JVI.78.20.11130-11141.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.

Authors:  John T West; Sally K Weldon; Stephanie Wyss; Xiaoxu Lin; Qin Yu; Markus Thali; Eric Hunter
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains.

Authors:  L Menéndez-Arias; A Abraha; M E Quiñones-Mateu; A Mas; M J Camarasa; E J Arts
Journal:  J Biol Chem       Date:  2001-05-15       Impact factor: 5.157

3.  Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.

Authors:  K Tokunaga; M L Greenberg; M A Morse; R I Cumming; H K Lyerly; B R Cullen
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and Quantiplex HIV-1 RNA version 3.0.

Authors:  P Swanson; V Soriano; S G Devare; J Hackett
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.

Authors:  V S Torre; A J Marozsan; J L Albright; K R Collins; O Hartley; R E Offord; M E Quiñones-Mateu; E J Arts
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

6.  Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection.

Authors:  Bluma G Brenner; Jean-Pierre Routy; Marco Petrella; Daniela Moisi; Maureen Oliveira; Mervi Detorio; Bonnie Spira; Vidal Essabag; Brian Conway; Richard Lalonde; Rafick-Pierre Sekaly; Mark A Wainberg
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1.

Authors:  O T Keppler; W Yonemoto; F J Welte; K S Patton; D Iacovides; R E Atchison; T Ngo; D L Hirschberg; R F Speck; M A Goldsmith
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Authors:  M E Quiñones-Mateu; S C Ball; A J Marozsan; V S Torre; J L Albright; G Vanham; G van Der Groen; R L Colebunders; E J Arts
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.

Authors:  Paul R Gorry; Joann Taylor; Geoffrey H Holm; Andrew Mehle; Tom Morgan; Mark Cayabyab; Michael Farzan; Hui Wang; Jeanne E Bell; Kevin Kunstman; John P Moore; Steven M Wolinsky; Dana Gabuzda
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

10.  The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein.

Authors:  M Shehu-Xhilaga; M Hill; J A Marshall; J Kappes; S M Crowe; J Mak
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

View more
  60 in total

1.  HIV-1 Group O Genotypes and Phenotypes: Relationship to Fitness and Susceptibility to Antiretroviral Drugs.

Authors:  Denis M Tebit; Hamish Patel; Annette Ratcliff; Elodie Alessandri; Joseph Liu; Crystal Carpenter; Jean-Christophe Plantier; Eric J Arts
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-16       Impact factor: 2.205

2.  Efficiency of human immunodeficiency virus type 1 postentry infection processes: evidence against disproportionate numbers of defective virions.

Authors:  James A Thomas; David E Ott; Robert J Gorelick
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

3.  Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.

Authors:  Victor G Kramer; Susan M Schader; Maureen Oliveira; Susan P Colby-Germinario; Daniel A Donahue; Diane N Singhroy; Randy Tressler; Richard D Sloan; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

4.  Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.

Authors:  Emily J Platt; Susan L Kozak; James P Durnin; Thomas J Hope; David Kabat
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

5.  Viral dynamics during primary simian immunodeficiency virus infection: effect of time-dependent virus infectivity.

Authors:  Naveen K Vaidya; Ruy M Ribeiro; Christopher J Miller; Alan S Perelson
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.

Authors:  Annette N Ratcliff; Wuxian Shi; Eric J Arts
Journal:  J Virol       Date:  2012-11-07       Impact factor: 5.103

7.  Multifaceted mechanisms of HIV inhibition and resistance to CCR5 inhibitors PSC-RANTES and Maraviroc.

Authors:  Michael A Lobritz; Annette N Ratcliff; Andre J Marozsan; Dawn M Dudley; John C Tilton; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

8.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

9.  Subtype-associated differences in HIV-1 reverse transcription affect the viral replication.

Authors:  Sergey Iordanskiy; Mackenzie Waltke; Yanjun Feng; Charles Wood
Journal:  Retrovirology       Date:  2010-10-12       Impact factor: 4.602

10.  The human immunodeficiency virus type 1 envelope confers higher rates of replicative fitness to perinatally transmitted viruses than to nontransmitted viruses.

Authors:  Xiaohong Kong; John T West; Hong Zhang; Danielle M Shea; Tendai J M'soka; Charles Wood
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.